449 related articles for article (PubMed ID: 16251295)
1. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study.
Lin MY; Carmeli Y; Zumsteg J; Flores EL; Tolentino J; Sreeramoju P; Weber SG
Antimicrob Agents Chemother; 2005 Nov; 49(11):4555-60. PubMed ID: 16251295
[TBL] [Abstract][Full Text] [Related]
2. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp.
Playford EG; Marriott D; Nguyen Q; Chen S; Ellis D; Slavin M; Sorrell TC
Crit Care Med; 2008 Jul; 36(7):2034-9. PubMed ID: 18552700
[TBL] [Abstract][Full Text] [Related]
3. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
Safdar A; van Rhee F; Henslee-Downey JP; Singhal S; Mehta J
Bone Marrow Transplant; 2001 Nov; 28(9):873-8. PubMed ID: 11781648
[TBL] [Abstract][Full Text] [Related]
4. Blood stream infections by Candida glabrata and Candida krusei: a single-center experience.
Choi HK; Jeong SJ; Lee HS; Chin BS; Choi SH; Han SH; Kim MS; Kim CO; Choi JY; Song YG; Kim JM
Korean J Intern Med; 2009 Sep; 24(3):263-9. PubMed ID: 19721864
[TBL] [Abstract][Full Text] [Related]
5. Prior antimicrobial exposure and the risk for bloodstream infection with fluconazole-non-susceptible Candida strains.
Hebert C; Villaran R; Tolentino J; Best L; Boonlayangoor S; Pitrak D; Lin M; Weber SG
Scand J Infect Dis; 2010 Jul; 42(6-7):506-9. PubMed ID: 20370357
[TBL] [Abstract][Full Text] [Related]
6. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
7. Breakthrough candidemia in patients with cancer differs from de novo candidemia in host factors and Candida species but not intensity.
Kontoyiannis DP; Reddy BT; Hanna H; Bodey GP; Tarrand J; Raad II
Infect Control Hosp Epidemiol; 2002 Sep; 23(9):542-5. PubMed ID: 12269454
[TBL] [Abstract][Full Text] [Related]
8. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome.
Dimopoulos G; Ntziora F; Rachiotis G; Armaganidis A; Falagas ME
Anesth Analg; 2008 Feb; 106(2):523-9, table of contents. PubMed ID: 18227310
[TBL] [Abstract][Full Text] [Related]
9. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.
Hachem R; Hanna H; Kontoyiannis D; Jiang Y; Raad I
Cancer; 2008 Jun; 112(11):2493-9. PubMed ID: 18412153
[TBL] [Abstract][Full Text] [Related]
10. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia.
Shorr AF; Lazarus DR; Sherner JH; Jackson WL; Morrel M; Fraser VJ; Kollef MH
Crit Care Med; 2007 Apr; 35(4):1077-83. PubMed ID: 17312565
[TBL] [Abstract][Full Text] [Related]
11. Is the incidence of candidemia caused by Candida glabrata increasing in Brazil? Five-year surveillance of Candida bloodstream infection in a university reference hospital in southeast Brazil.
Moretti ML; Trabasso P; Lyra L; Fagnani R; Resende MR; de Oliveira Cardoso LG; Schreiber AZ
Med Mycol; 2013 Apr; 51(3):225-30. PubMed ID: 22920712
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).
Leroy O; Gangneux JP; Montravers P; Mira JP; Gouin F; Sollet JP; Carlet J; Reynes J; Rosenheim M; Regnier B; Lortholary O;
Crit Care Med; 2009 May; 37(5):1612-8. PubMed ID: 19325476
[TBL] [Abstract][Full Text] [Related]
13. Nosocomial Candida krusei fungemia in cancer patients: report of 10 cases and review.
Krcmery V; Spanik S; Kunova A; Trupl J; Grausova S; Krupova I; Mateicka F; Pichnova E; Grey E; Sabo A
J Chemother; 1999 Apr; 11(2):131-6. PubMed ID: 10326744
[TBL] [Abstract][Full Text] [Related]
14. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer.
Bodey GP; Mardani M; Hanna HA; Boktour M; Abbas J; Girgawy E; Hachem RY; Kontoyiannis DP; Raad II
Am J Med; 2002 Apr; 112(5):380-5. PubMed ID: 11904112
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for nosocomial candiduria due to Candida glabrata and Candida albicans.
Harris AD; Castro J; Sheppard DC; Carmeli Y; Samore MH
Clin Infect Dis; 1999 Oct; 29(4):926-8. PubMed ID: 10589912
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology and risk factors for nosocomial Non-Candida albicans candidemia in adult patients at a tertiary care hospital in North China.
Ding X; Yan D; Sun W; Zeng Z; Su R; Su J
Med Mycol; 2015 Sep; 53(7):684-90. PubMed ID: 26229153
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for fluconazole-resistant candidemia.
Garnacho-Montero J; Díaz-Martín A; García-Cabrera E; Ruiz Pérez de Pipaón M; Hernández-Caballero C; Aznar-Martín J; Cisneros JM; Ortiz-Leyba C
Antimicrob Agents Chemother; 2010 Aug; 54(8):3149-54. PubMed ID: 20498325
[TBL] [Abstract][Full Text] [Related]
18. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections.
Safdar A; Hanna HA; Boktour M; Kontoyiannis DP; Hachem R; Lichtiger B; Freireich EJ; Raad II
Cancer; 2004 Dec; 101(12):2859-65. PubMed ID: 15529309
[TBL] [Abstract][Full Text] [Related]
19. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
Klevay MJ; Horn DL; Neofytos D; Pfaller MA; Diekema DJ;
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):152-7. PubMed ID: 19376667
[TBL] [Abstract][Full Text] [Related]
20. Candida non-albicans versus Candida albicans fungemia in the non-neonatal pediatric population.
Dutta A; Palazzi DL
Pediatr Infect Dis J; 2011 Aug; 30(8):664-8. PubMed ID: 21372750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
